Next Article in Journal
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression
Previous Article in Journal
Current Status of Molecularly Targeted Therapeutics in Blood Cancers
 
 
Article

Article Versions Notes

Int. J. Mol. Sci. 2025, 26(21), 10513; https://doi.org/10.3390/ijms262110513
Action Date Notes Link
article html file updated 31 October 2025 03:22 CET Update https://www.mdpi.com/1422-0067/26/21/10513/html
article pdf uploaded. 31 October 2025 03:20 CET Updated version of record https://www.mdpi.com/1422-0067/26/21/10513/pdf
article xml uploaded. 31 October 2025 03:20 CET Update https://www.mdpi.com/1422-0067/26/21/10513/xml
article xml file uploaded 31 October 2025 03:20 CET Update -
article html file updated 29 October 2025 14:14 CET Original file -
article supplementary file uploaded. 29 October 2025 14:12 CET - https://www.mdpi.com/1422-0067/26/21/10513#supplementary
article pdf uploaded. 29 October 2025 14:12 CET Version of Record https://www.mdpi.com/1422-0067/26/21/10513/pdf-vor
article xml uploaded. 29 October 2025 14:12 CET Update -
article xml file uploaded 29 October 2025 14:12 CET Original file -
Back to TopTop